Article Details

Pluristem Therapeutics (NASDAQ:PSTI) Stock Rating Lowered by Zacks Investment Research

Retrieved on: 2021-12-18 17:06:07

Tags for this article:

Click the tags to see associated articles and topics

Pluristem Therapeutics (NASDAQ:PSTI) Stock Rating Lowered by Zacks Investment Research. View article details on hiswai:

Excerpt

The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.05.

Article found on: etfdailynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up